10559675 03/01/2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS EXPRESS		JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:43:23 ON 01 MAR 2009

=> FILE REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 19:43:32 ON 01 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 FEB 2009  HIGHEST RN 1113101-98-6
DICTIONARY FILE UPDATES:  27 FEB 2009  HIGHEST RN 1113101-98-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10559675.str
```





chain nodes :
9 10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
3-9 9-10 10-11 11-12 11-14 12-13 13-15
ring bonds :
1-2 1-5 1-8 2-3 3-4 4-5 5-6 6-7 7-8
exact/norm bonds :
1-2 1-5 1-8 2-3 3-4 4-5 5-6 6-7 7-8 9-10 10-11 11-12 11-14 12-13
13-15
exact bonds :
3-9

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> S L1
SAMPLE SEARCH INITIATED 19:44:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             0 TO         0
PROJECTED ANSWERS:                0 TO         0

L2            0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\105596753.str
```





```
chain nodes :
9  10  11  12
ring nodes :
1  2  3  4  5  6  7  8
chain bonds :
3-9  9-10  10-11  11-12
ring bonds :
1-2  1-5  1-8  2-3  3-4  4-5  5-6  6-7  7-8
exact/norm bonds :
1-2  1-5  1-8  2-3  3-4  4-5  5-6  6-7  7-8  9-10  10-11  11-12
exact bonds :
3-9


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:CLASS  10:CLASS
11:CLASS  12:CLASS



L3      STRUCTURE UPLOADED

=> D
L3 HAS NO ANSWERS
L3               STR
```

Structure attributes must be viewed using STN Express query preparation.

```
=> S L3
SAMPLE SEARCH INITIATED 19:45:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       18 TO ITERATE

100.0% PROCESSED       18 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          106 TO      614
PROJECTED ANSWERS:               5 TO      234

L4            5 SEA SSS SAM L3

=> S L3 FULL
FULL SEARCH INITIATED 19:45:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      320 TO ITERATE

100.0% PROCESSED      320 ITERATIONS                               42 ANSWERS
SEARCH TIME: 00.00.01

L5           42 SEA SSS FUL L3

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   187.32     187.54

FILE 'CAPLUS' ENTERED AT 19:45:49 ON 01 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Mar 2009 VOL 150 ISS 10
FILE LAST UPDATED: 27 Feb 2009 (20090227/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> S L5
L6   2 L5

=> D IBIB ABS HISTR TOT
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

```
HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D IBIB ABS HISTR TOT
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
```

```
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D L5  IBIB ABS HITSTR TOT
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:N


=> D L6 IBIB ABS HISTR TOT
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
```

```
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D L6 IBIB ABS HITSTR TOT
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1127390 CAPLUS
DOCUMENT NUMBER: 141:74577
TITLE: Preparation of imidazothiadiazolesulfonamides for treatment of neuronal disorders and proliferative disease
INVENTOR(S): Jaquith, James B.; Dillard, John W.
PATENT ASSIGNEE(S): Aeguis Therapeutics Inc., Can.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111060	A1	20041223	WO 2004-CA873	20040614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2527906	A1	20041223	CA 2004-2527906	20040614
EP 1636242	A1	20060322	EP 2004-737814	20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1833956	A	20060920	CN 2004-80022222	20040614
JP 2006527089	T	20061130	JP 2006-533592	20040614
US 20070112043	A1	20070517	US 2005-539675	20051206
IN 2005MN02573	A	20070706	IN 2005-MN2573	20051212
PRIORITY APPLN. INFO.:			US 2003-477947P P	20030613
			WO 2004-CA873 W	20040614

OTHER SOURCE(S): MARPAT 141:74577
GI



AB Title compds. [I; R1 = CONR3, CO(CH2)nN(CO)p(OCH2CH2)mOR10,

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Uses)
(prepn. of imidazothiadiazolesulfonamides for treatment of neuronal disorders and proliferative disease)

RN 812694-94-9 CAPLUS
CN Acetamide, N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]- (CA INDEX NAME)



RN 812694-95-0 CAPLUS
CN Butanamide, N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]- (CA INDEX NAME)

RN 812694-96-1 CAPLUS
CN Carbamic acid, [(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]-, 2,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 812694-97-2 CAPLUS
CN Carbamic acid, [2-oxo-2-[[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 812694-99-4 CAPLUS
CN Acetamide, 2-amino-N-[(6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CO(CH2)1-9NR12R13; R2 = H, R5 = H, Me, (substituted) FNCH2; R6 = fluoroalkyl, (substituted) aryl, heteroaryl, biphenyl, di-Ph ether, coumarinyl, adamantyl, etc.; R9 = (substituted) alkyl, aryl; R10 = H, (substituted) alkyl, aryl, heteroaryl; R11, R13 = H, (substituted) alkyl, aralkyl, aryl, heteroaryl; R12, R13 = H, (substituted) alkyl, aralkyl, aryl, heteroaryl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl; R12R13 = atoms to form a 5-7 membered (substituted) heterocyclyl; n = 0-6; p = 0,

1; m = 0-22; q = 1-5], were prepd. Thus, I (R3, R2, R5 = H; R6 = Ph) was stirred with AcCl and Et3N in THF for 16 h to give 95% I (R3 = Ac, R2, R5 = H, R6 = Ph). The latter showed oxidn. of 10 mg/mL in PBS/HPCL. I were active in reducing loss of sensory nerve conduction velocity in rats treated with cisplatin.

IT 1026672-12-6 1026723-06-7
RL: PREP (Prophetic)
(Preparation of imidazothiadiazolesulfonamides for treatment of neuronal disorders and proliferative disease.)

RN 1026672-12-6 CAPLUS
CN Butanamide, N-[[6-(3'-methoxy[1,1'-biphenyl]-4-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 1026723-06-7 CAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[[6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



IT 812694-94-9P 812694-95-0P 812694-96-1P
812694-97-2P 812694-99-4P 812697-00-0P
812697-03-3P 812697-05-5P 812697-07-7P
812697-08-8P 812697-09-9P 812697-10-2P
812697-11-3P 812697-12-4P 812697-13-5P
812697-14-6P 812697-15-7P 812697-16-8P
812697-17-9P 812697-18-0P 812697-19-1P
812697-20-4P 812697-21-5P 812697-22-6P
812697-23-7P 812697-24-8P 812697-25-9P
812697-26-0P 812697-27-1P 812697-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CM 1

CRN 812696-98-3
CMF C12 H11 N5 O3 S2

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 812697-00-0 CAPLUS
CN Butanoic acid, 4-oxo-4-[[[6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]- (CA INDEX NAME)



RN 812697-02-2 CAPLUS
CN Carbamic acid, [(1S)-3-(methylthio)-1-[[[6-(phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl)sulfonyl]amino]carbonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-06-5 CAPLUS
CN Butanamide, 2-amino-4-(methylthio)-N-[[6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 812697-04-4
CMF C15 H17 N5 O3 S3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 812697-07-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[6-phenylimidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 812697-06-6

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-11-3 CAPLUS
CN Butanamide, N-[[6-[3,4-dihydro-2H-1,5-benzodioxepin-7-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

RN 812697-12-4 CAPLUS
CN Butanamide,
N-[[6-[4-(4-morpholinyl)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-13-5 CAPLUS
CN Acetamide, N-[[6-[3'-methoxy[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

RN 812697-14-6 CAPLUS
CN Acetamide,
2-methoxy-N-[[6-[3'-methoxy[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CMF C15 H15 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 812697-08-8 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[[6-(4-fluorophenyl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-09-9 CAPLUS
CN Acetamide, N-[[6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-10-2 CAPLUS
CN Acetamide, N-[[6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-2-methoxy- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-15-7 CAPLUS
CN Acetamide,
N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-16-8 CAPLUS
CN Butanamide,
N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

RN 812697-17-9 CAPLUS
CN Acetamide,
2-(2-methoxyethoxy)-N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

RN 812697-18-0 CAPLUS
CN Acetamide,
2-[2-(2-methoxyethoxy)ethoxy]-N-[[6-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



PAGE 1-B

RN 812697-19-1 CAPLUS
CN Carbamic acid, [[4-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 812697-20-4 CAPLUS
CN Acetamide, N-[[4-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-21-5 CAPLUS
CN Acetamide, N-[[4-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-2-methoxy- (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-26-0 CAPLUS
CN Carbamic acid, [2-[[[4-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 812697-27-1 CAPLUS
CN Carbamic acid, [(2S)-4-[(aminoiminomethyl)amino]-2-[[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

RN 812697-37-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[3,10-dioxo-10-[[6-phenylimidazo[2,1-b]-

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 812697-22-6 CAPLUS
CN Butanamide, N-[[4-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-23-7 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]- (CA INDEX NAME)



RN 812697-24-8 CAPLUS
CN Carbamic acid, [[4-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 812697-25-9 CAPLUS
CN Carbamic acid, [(3S)-1-[[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 812697-28-2 CAPLUS
CN Carbamic acid, [1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene]-, [[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]methyl ester (9CI) (CA INDEX NAME)

RN 812697-29-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 812697-30-6 CAPLUS
CN Carbamic acid, [(1S)-1-[[[[6-[4-(4-chlorophenoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:691276 CAPLUS
DOCUMENT NUMBER: 139:289270
TITLE: Preparation of imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides as neuroprotective agents
INVENTOR(S): Jaquith, James B.; Villeneuve, Gerald; Boudreault, Alain; Morris, Stephen; Durkin, Jon; Gillard, John W.; Hewitt, Kimberley; Marsh, Nicholas H.
PATENT ASSIGNEE(S): Aegera Therapeutics Inc., Can.
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003058890	A1	20030626	WO 2002-CA1942	20021216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EA, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2364965	A1	20030614	CA 2001-2364965	20011214
CA 2469953	A1	20030626	CA 2002-2469953	20021216
AU 2002350333	A1	20030630	AU 2002-350333	20021216
AU 2002350333	B2	20080821		
EP 1463735	A1	20041006	EP 2002-784979	20021216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005519982	T	20050707	JP 2003-552772	20021216
US 20050069492	A1	20050331	US 2004-498548	20040614
US 7250219	B2	20070731		
US 20070221476	A1	20070125	US 2006-399010	20060405
US 20070221416	A1	20070125	US 2006-399806	20060406
US 20070288059	A1	20070419	US 2006-399033	20060406
US 20070239769	A1	20071011	US 2007-797664	20070507
US 20070239766	A1	20071011	US 2007-797665	20070507
US 20070265319	A1	20071115	US 2007-797663	20070507
US 20090042953	A1	20090212	US 2008-99123	20080407
PRIORITY APPLN. INFO.:			CA 2001-2364965 A	20011214
			WO 2002-CA1942 W	20021216
			US 2004-498548 A3	20040614
			US 2007-797665 A1	20070507

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 550366-44-4 CAPLUS
CN Carbamic acid, [[4-[4-[2-(acetyloxy)ethoxy]phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT: 0 THERE ARE 0 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 139:289270
GI



AB This invention relates to imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides (shown as I, variables defined below, e.g., 6-phenylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide) and their use as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. For I: R1 and R3 = H, lower alkyl, substituted lower alkyl, and fluoroalkyl; R5 = H, halo, cyano, azido, thiocyanato, formyl, (un)substituted lower alkyl, fluoroalkyl, (un)substituted aralkyl, (un)substituted aryl, (un)substituted heteroaryl; R6 = H, (un)substituted lower alkyl, (un)substituted fluoroalkyl, (un)substituted aryl, (un)substituted heteroaryl, oxhumanity, and (un)substituted coumarinyl, etc., addnl. details including provisos are given in the claims. Pharmacol. results are reported for some I for rescue from anti-neuronal growth factor killing of sympathetic ganglia neurons, in vitro protection of sympathetic ganglia neurons from Taxol, cisplatin and vincristine killing, protection of motor neurons in lever V of the motor cortex, outreatment of BA4&0 and CV2&0 cell line with Taxol and 6-phenylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide, protection of Sprague Dawley rats from Taxol-induced neuropathies, sciatic nerve crush injury model, optical stroke model, CA II inhibition, and neuroprotection of cortical neurons in the presence of B-amyloid. Although the methods of preparation are not claimed, 153 example prepns. of I are included.
IT 550366-43-3P, N-Boc-6-[4-(2-hydroxyethoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide 550366-44-4P, N-Boc-6-[4-(2-acetoxyethoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides as neuroprotective agents)
RN 550366-43-3 CAPLUS
CN Carbamic acid, [[6-[4-(2-hydroxyethoxy)phenyl]imidazo[2,1-b]-1,3,4-thiadiazol-2-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

```
=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    13.28     200.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.64      -1.64

STN INTERNATIONAL LOGOFF AT 19:48:12 ON 01 MAR 2009
```